A Study to Assess the Safety, Tolerability, and Effects of MK-0974 on Exercise Tolerance in Patients With Stable Angina (MK-0974-014 AM3)
This study has been completed.
Information provided by:
First received: February 10, 2011
Last updated: February 24, 2011
Last verified: February 2011
This study will assess the safety of MK-0974 in coronary artery disease (CAD) participants with stable angina during exercise treadmill testing and evaluate whether calcitonin gene-related peptide (CGRP) receptor antagonism by MK-0974 reduces exercise tolerance in these participants.
Coronary Heart Disease
Calcitonin Gene-related Peptide Receptor
Drug: Placebo to MK-0974
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
||A Double-Blind, Randomized, Placebo-Controlled, 2-Period Crossover Study to Assess the Safety, Tolerability, and Effects of MK-0974 on Exercise Tolerance in Patients With Stable Angina
Primary Outcome Measures:
- Number of participants with clinical and laboratory adverse events [ Time Frame: Up to 6 hours postdose, and up to 14 days after last dose ] [ Designated as safety issue: Yes ]
- Difference in total exercise duration on the treadmill test following administration of MK-0974 vs. placebo [ Time Frame: Approximately 15 minutes ] [ Designated as safety issue: No ]
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||February 2009 (Final data collection date for primary outcome measure)
Experimental: MK-0974 (600 mg)
Gel capsules containing 300 mg MK-0974, orally, 2 capsules as a single dose, OR solid tablets containing 280 mg MK-0974, orally, 2 tablets as a single dose
Experimental: MK-0974 (900 mg)
Gel capsules containing 300 mg MK-0974, orally, 3 capsules as a single dose
Placebo Comparator: Placebo
Drug: Placebo to MK-0974
Placebo to MK-0974 gel capsules or solid tablets, orally, 2 or 3 capsules or tablets as a single dose
|Ages Eligible for Study:
||18 Years to 85 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Participant has clinically documented stable coronary artery disease as demonstrated by coronary angiography, echocardiogram, or stress test, etc., or participant is on stable doses of current medication for the treatment of coronary artery disease for a minimum of 30 days.
- Participant has a history of stable angina (chronic stable angina pectoris that is triggered by physical effort and relieved by rest and/or sublingual nitroglycerin) for at least 3 months prior to study start, with no intervening symptoms of unstable angina.
- Participant is able to demonstrate reproducibly positive exercise tests by completing treadmill tests on 2 separate days, within 1-8 days.
- Participant agrees to refrain from drinking alcohol from 24 hours prior to study drug administration, on study procedure days, and until release from the study facility.
- Participants agrees to refrain from smoking from midnight before study procedures until study procedures are complete for the day.
- Participant has no clinically significant abnormality on screening laboratory safety assessment.
- Participant agrees to refrain from unaccustomed strenuous physical activity from the prestudy (screening) visit, throughout the study, and until the post-study visit.
- Participant is pregnant (positive serum beta-human chorionic gonadotropin [β-hCG] test at prestudy), breast-feeding, or is a female expecting to conceive within the projected duration of the study. Postmenopausal women who are currently using hormone replacement therapy are excluded from participation in the study.
- Participant has electrocardiogram (ECG) findings that interfere with ECG interpretation or may cause false positive stress test (e.g., > 1 mm horizontal or downsloping ST-segment depression at rest in any standard electrocardiographic lead, Lown-Ganong-Levine syndrome, Wolff-Parkinson-White (WPW), left bundle branch block (LBBB), left ventricular hypertrophy (LVH) with repolarization abnormality, pectus excavatum, ventricular pacemaker, etc.). Note: these ECG findings may affect stress test results; there may be other findings that have not been included which may affect test results. These ECG findings are exclusions only if these findings may jeopardize interpretation of stress test results.
- Participant has heart rate-corrected QT interval (QTc) (Bazett) > 500 ms on resting ECG.
- Participant has uncontrolled high blood pressure at prestudy screening.
- Participant has a baseline heart rate of <40 or >96 beats per minute at screening.
- Participant has unstable angina, hypertrophic cardiomyopathy, valvular heart disease, congenital cardiac defect, severe aortic stenosis, class III or IV heart failure.
- Participant has diabetes and is, in the opinion of the investigator, unable to comply with the pre-and post-dosing fasting requirements of the study due to risks of hypoglycemia.
- Participant is unable to withhold acetohexamide, chlorpropamide, glimepride, glimepiride and pioglitazone, glimepride and rosiglitazone, glipizide, glipizide and metformin, glyburide, glyburide and metformin, tolazamide, tolbutamide, or any other medication, that in the opinion of the investigator is likely to result in hypoglycemia within 8 hours of dosing.
- Participant has had myocardial infarction or coronary revascularization within the prior 2 months.
- Participant has acute myocarditis or pericarditis.
- Participant is obese, with adipose tissue which may interfere with ECG interpretation, or in the opinion of the investigator, whose obesity puts the participant at medical risk.
- Participant has clinically significant hypokalemia or hypomagnesemia.
- Participant has a history of any illness that, in the opinion of the investigator, might confound the results of the study or poses an additional risk to the participant by their participation in the study.
- Participant must not have taken any of the following medications in the time frame specified: Participant is unable to refrain from or anticipates the use of any herbal remedies beginning approximately 2 weeks (or 5 half-lives) prior to administration of the initial dose of study drug, throughout the study (including washout intervals between treatments), until the post-study visit; participant is unable to refrain from taking a drug metabolized by cytochrome P450 3A4 (CYP3A4) until at least 48 hours post dose (the exact length of time a specific drug metabolized by CYP3A4 is withheld is dependent on the therapeutic index of the drug and the extent to which it is metabolized by CYP3A4); participant consumes excessive amounts of alcohol which, in the opinion of the investigator, puts the participant at medical risk by participating in the study (participant has clinical [e.g., enlarged liver] or laboratory evidence [e.g., elevated alanine aminotransferase (ALT)], of chronic alcoholism or drug abuse, in the opinion of the investigator); participants is currently a regular user (including: recreational use") of any illicit drugs or has a history of drug (including alcohol) abuse within approximately 6 months; participant has taken potent CYP3A4 inhibitors, including but not limited to cyclosporine, systemic (oral/intravenous) itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin, nefazodone, human immunodeficiency virus (HIV) protease inhibitors within 1 month prior to dosing with MK-0974 or placebo and throughout the study period; participant has taken moderate CYP3A4 inhibitors, including but not limited to verapamil, diltiazem, fluconazole, fluvoxamine, fluoxetine, aprepitant within 2 weeks prior to dosing with MK-0974 or placebo and throughout the study period; participant has taken potent CYP3A4 inducers, including but not limited to rifampicin, rifabutin, carbamazepine, phenytoin, barbiturates, systemic glucocorticoids (replacements and inhaled are permitted), nevirapine, efavirenz, pioglitazone, primidone, St. John's wort within 1 month prior to dosing MK-0974 or placebo and throughout the study period; participant has taken triptans, ergot alkaloids within 48 hours prior to dosing MK-0974 or placebo and throughout the study period; participant has taken digoxin, medications that prolong QTc interval such as Class IA and Class III anti-arrhythmics (quinidine, procainamide, amiodarone, sotalol, etc), Seldane (terfenadine), Hismanal (astemizole), Propulsid (cisapride) within 1 month prior to dosing MK-0974 or placebo and throughout the study period; participant has received an investigational medication within 4 weeks prior to the prestudy (screening) visit.
- Participant has a history of multiple and/or severe allergies, or has had an anaphylactic reaction or intolerability to prescription or non-prescription drugs or food.
- There is any concern by the investigator regarding the safe participation of a participant in the study, or for any other reason the investigator considers the participant inappropriate to participate in the study.
No Contacts or Locations Provided
No publications provided
||Vice President of Late Stage Development, Merck Sharp & Dohme Corp
History of Changes
|Other Study ID Numbers:
|Study First Received:
||February 10, 2011
||February 24, 2011
||United States: Food and Drug Administration
Keywords provided by Merck:
coronary artery disease
calcitonin gene-related peptide
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on June 18, 2013
Coronary Artery Disease
Signs and Symptoms
Arterial Occlusive Diseases
Calcitonin Gene-Related Peptide
Bone Density Conservation Agents
Physiological Effects of Drugs